---
title: "The United Laboratories International Holdings Limited (03933.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/03933.HK.md"
symbol: "03933.HK"
name: "The United Laboratories International Holdings Limited"
industry: "Pharmaceuticals"
---

# The United Laboratories International Holdings Limited (03933.HK)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Location | HK Market |
| Website | [www.tul.com.cn](https://www.tul.com.cn) |

## Company Profile

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:12.000Z

**Overall: C (0.41)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 20 / 48 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.81% |  |
| Net Profit YoY | 5.47% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.46 |  |
| Dividend Ratio | 4.59% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 24.84B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 15.29B |  |


**Multi Score**: C

#### Profit Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 21.05% | A |
| Profit Margin | 21.72% | A |
| Gross Margin | 52.19% | B |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.81% | C |
| Net Profit YoY | 5.47% | C |
| Total Assets YoY | 31.35% | A |
| Net Assets YoY | 17.16% | A |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 460.45% | C |
| OCF YoY | 0.81% | C |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.54 | C |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 46.96% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - The United Laboratories International Holdings Limited",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "A",
      "indicators": [
        {
          "name": "ROE",
          "value": "21.05%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "21.72%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "52.19%",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.81%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "5.47%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "31.35%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "17.16%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "460.45%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "0.81%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.54",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "46.96%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | HENGRUI PHARMA (HK.1276) | A | B | C | A | B | B |
| 02 | HANSOH PHARMA (HK.3692) | A | B | C | A | C | B |
| 03 | SINO BIOPHARM (HK.1177) | B | B | C | B | B | B |
| 04 | CMS (HK.867) | B | B | C | A | B | B |
| 05 | SIMCERE PHARMA (HK.2096) | B | B | B | C | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 7.40 | 4/51 | 9.73 | 8.45 | 7.33 |
| PB | 1.46 | 25/51 | 1.87 | 1.61 | 1.44 |
| PS (TTM) | 1.61 | 18/51 | 1.95 | 1.70 | 1.55 |
| Dividend Yield | 4.59% | 11/51 | 4.77% | 4.42% | 3.81% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-05T16:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 7 | 70% |
| Overweight | 0 | 0% |
| Hold | 3 | 30% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 12.59 |
| Highest Target | 22.26 |
| Lowest Target | 13.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/03933.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/03933.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/03933.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.